Provided by Tiger Trade Technology Pte. Ltd.

REMEGEN

76.000
+2.2503.05%
Volume:2.57M
Turnover:192.12M
Market Cap:42.83B
PE:50.39
High:76.200
Open:73.800
Low:72.600
Close:73.750
52wk High:126.600
52wk Low:63.300
Shares:563.61M
HK Float Shares:208.58M
Volume Ratio:1.30
T/O Rate:1.23%
Dividend:- -
Dividend Rate:- -
EPS(LYR):1.508
ROE:109.10%
ROA:39.01%
PB:4.41
PE(LYR):50.39
PS:4.58

Loading ...

Stock Track | REMEGEN Plummets 5.19% Intraday as Profit-Taking Follows Fully Priced-In Catalysts

Stock Track
·
Apr 23

Profitability Reaches 17 Biotech Firms Including BeiGene, Innovent, Beta Pharma, and Remegen

Deep News
·
Apr 21

Why RemeGen (SEHK:9995) Is Up 13.1% After First HER2 ADC–Immunotherapy Approval in China

Simply Wall St.
·
Apr 18

RemeGen Schedules 28 April 2026 Board Meeting to Review Q1 2026 Unaudited Results

Bulletin Express
·
Apr 16

CATL Reports 48.52% Surge in Q1 Net Profit to RMB 20.74 Billion

Stock News
·
Apr 16

National Data Administration Proposes Token Trading Exploration; Central Bank Adjusts Overseas Loan Ratios

Stock News
·
Apr 16

Remegen Receives $650 Million Upfront Payment from AbbVie for RC148 Exclusive Licensing Agreement

Stock News
·
Apr 15

Stock Track | REMEGEN Soars 5.17% Intraday on New Drug Approval and Strong Earnings Turnaround

Stock Track
·
Apr 15

BUZZ-RemeGen set for best day in two weeks on China nod for tumour drug application

Reuters
·
Apr 13

RemeGen Drug Approved For Cancer Indication

MT Newswires Live
·
Apr 13

Stock Track | REMEGEN Soars 5.09% Intraday on New Drug Approval and Strong Revenue Growth

Stock Track
·
Apr 13

Hong Kong Grants First Stablecoin Issuer Licenses as Iran-US Talks Show Major Rifts

Stock News
·
Apr 13

RemeGen receives NMPA approval for Disitamab Vedotin + Toripalimab in HER2-expressing urothelial carcinoma, securing fifth on-label use

Bulletin Express
·
Apr 10

RemeGen Maintains 564.48 Million Share Capital; Confirms Public Float Compliance for March 2026

Bulletin Express
·
Apr 09

RemeGen (HKG:9995) Is Posting Healthy Earnings, But It Is Not All Good News

Simply Wall St.
·
Apr 04

China International Capital Corp. Highlights Positive Trends in Domestic Innovative Drug Sector, Anticipates Key Academic Developments in 2026

Stock News
·
Apr 03

China International Capital Corporation Maintains Outperform Rating on REMEGEN, Raises Target Price to HK$133.7

Stock News
·
Apr 03

Lilly's Oral GLP-1 Weight Loss Drug Receives FDA Approval, Offering Daily Pill Alternative to Injections

Deep News
·
Apr 03

RemeGen (SEHK:9995) Is Up 30.0% After New HER2-Low Breast Cancer Approval Has The Bull Case Changed?

Simply Wall St.
·
Apr 03

RemeGen Receives Chinese Regulatory Nod for RC288 Clinical Trial

MT Newswires Live
·
Apr 02